Richard Ian Griffiths - 11 Jul 2025 Form 4 Insider Report for Silence Therapeutics plc (SLN)

Reporting relationship: 10%+ Owner
Issuer ticker: SLN
Reported as of: 11 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jul 2025, 14:58:36 UTC
Prior SEC filing: 10 Jul 2025
Next SEC filing: 23 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Richard Ian Griffiths

Key filing fact

Richard Ian Griffiths filed Form 4 for Silence Therapeutics plc (SLN) on 16 Jul 2025.

Key facts

This page summarizes Richard Ian Griffiths's Form 4 filing for Silence Therapeutics plc (SLN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Jul 2025, 14:58.

Change

Previous filing in this sequence was filed on 10 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001846370 Primary reporting owner

Griffiths Richard Ian

Relationship: 10%+ Owner
Address: FLOOR 1 LIBERATION STATION, ESPLANADE, ST HELIER, JERSEY
Signature: /s/ Richard Ian Griffiths
Signature date: 16 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLN transaction Derivative

American Depositary Shares

Purchase

Transaction value
Shares: +28,000
Change %: +0.24%
Price
Shares after: 11,715,365
Date: 11 Jul 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 84,000
Exercise price: $6.43
Footnotes: F1

SLN transaction Derivative

American Depositary Shares

Purchase

Transaction value
Shares: +43,293
Change %: +0.37%
Price
Shares after: 11,758,658
Date: 15 Jul 2025
Ownership: See Footnote
Underlying class: Ordinary Shares
Underlying amount: 129,879
Exercise price: $6.40
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

Footnote F2

The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.